CA2348792A1 - Neuro-immune-endocrine regulating device and treatment - Google Patents
Neuro-immune-endocrine regulating device and treatment Download PDFInfo
- Publication number
- CA2348792A1 CA2348792A1 CA002348792A CA2348792A CA2348792A1 CA 2348792 A1 CA2348792 A1 CA 2348792A1 CA 002348792 A CA002348792 A CA 002348792A CA 2348792 A CA2348792 A CA 2348792A CA 2348792 A1 CA2348792 A1 CA 2348792A1
- Authority
- CA
- Canada
- Prior art keywords
- medical device
- immune
- medical
- light
- neuro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0618—Psychological treatment
Abstract
This invention comprises a method and device especially designed for treating neuro-immune-endocrine dysfunction by photostimulating pigmented neurons of the orbital areas of the cerebral cortex with filtered light, so as to achieve a modulation of the hypothalamus-pituitary-adrenal axis and/or of the brain-bone marrow axis (or some other axis). The method of treatment consists of placing the tips of the lens-holders of the device consecutively at three or more contiguous sites of each orbtial roof for 2 to 4 minutes per site, twice weekly, for two months and for further periods as required. Patients are treated in a recumbent (or seated) position with eyes closed. No light is sent through the eyes. This treatment is used for essential hypertension, chronic pharyngitis, rheumatoid arthritis, allergies (especially respiratory), immunodeficiency arising from any cause, cancer, systemic lupus erythematosus, eczema, psoriasis, thyroid desease, viral syndromes and other pathologies involving neuro-immune-endocrine dysfunction. The device is equipped with (at least) two lens-holders, each with a filter transmitting wavelengths peaking at 350-400nm and 750-800nm (or with other appropriate specifications), quartz glass, biconvex lens of 50 dioptres (minimum) and low-powered medical bulb or other light source. In the hand-held model, the holders are mounted in a rectangular platic casing containing a printed circuit, pivot for positioning the holders, an output regulator with a digital display for voltage/mA. The input is 6V DC (battery model), 220V DC (mains model) and output is 0.5-3V DC
(variable); 50-300 mA. The hospital model is equipped with computerized circuits comprising craniometric, densitometric, and other programmable functions.
(variable); 50-300 mA. The hospital model is equipped with computerized circuits comprising craniometric, densitometric, and other programmable functions.
Description
NEURO-IMMLfNE-ENDOCRINE REGULATING
DEVICE AND TREATMENT
TECHNIC',AL FIELD AND BACKGROUND
This invention, which comprises a device and method of treatment, applies principles of photobiolo~y to the field of neuro-immune-endocrinology.
Intended for the treatment of neuro-unmune-endocrine dysfunction, the invention is designed to photostirnulate pigmented neurons in the orbital areas of the cerebral cortex with filtered light. It is known that there are direct afferent and efferent projections between the orbital areas of the cerebral cortex and the hypothalamus. The hypothalamus-pituitary-adrenal axis and the brain-bone marrow axis have a central role in neuro-immune-endocrine regula~ian. Several experiments have shown us that the method of photostimulation, with our device, of the orbital areas of the cerebral cortex can produce a modulation of the hypothalamus-pituitary-adrenal axis andlor of the brain-bone marrow axis (or conceivably of some other axis), crucial for treating the following pathologies: essential hypertension, chronic pharyngitis, rheumatoid arthritis, allergies (especi;~lly respiratory), immunodeficiency arising from any cause, cancer, systemic lupus erythematosus, eczema, psoriasis, thyroid disease, viral syndromes and other pathologies involving neuro-immune-endocrine dysfunction.
For most of the afore-mentioned diseases, conventional (pharmacological) treatment offers benefits that do not always outweigh the risks to the patient. The device we have invented uses filtered light and no medication of any kind.
Treatment with the device is painless, non-invasive and non-toxic.
Insert on page 1 before "DISCLOSURE OF THE INVENTION"
FR-A-2 746 321 discloses a deuce for 'treatment without surgery, chemotherapy or radiotherapy of (auto-immune) pathologies characterized by immunological imbalance.' The device includes means providing light and filters for blocking LTV and IR.
This device was tested on a pre-experimental basis for two months. Its effectiveness was found to be eactremely limited. Clinical improvement was not significant and not sustained for more than a week.
rt: ~: ;,t:~.~r.
DISCLOSUP;E OF THE INVENT10N
The device has optical .and electronic components with (but not restricted to) the 30 following specifications" ,ill such technical specifications concerning the device provided throughout this document are for the purpose of illustration, not of linvtation.
In the hand-held model, the optical components comprise two lens-holders made of plastic or other light-weiglht material (of cylindrical or other form). Each holder is equipped with a quartz glass (diameter : about 9mrn, thickness : 1, lmm), placed at the 35 tip, a biconvex lens (minimum SO dioptres, diameter : about 9mm, thickness : 3mm ;
or of other specifications suitable for photostimulating the orbital areas of the cerebral cortex) placed at the appropriate focal distance inside. In front of each biconvex lens is a filter with (or without) a diffuser (diameter : about 9mm, thickness : lmm), transmitting wavelengths with peaks at 350-400nm and 750-800nm (or with other peaks suitable for photostimulating the orbital areas of the cerebral cortex).
A low-s powered (2.7V-4V) medical bulb (or light source of similar power) is positioned behind each biconvex lens near the base of each holder.
In the hand-held model of the device, the two holders are mounted in a rectangular plastic casing (approx. 1:32mm x 170mm) which contains a printed circuit, battery housing (for the battery model) and a pivot mechanism for positioning the holders at different sites of the orbital roofs. ~fhe input is 6V DC (battery model), (mains model) and output is 0.5 - 3 V DC (variable) ; 50 - 300 mA . The device is equipped with an output regulator, and a digital display showing voltage or mA.
A hospital model of the device is planned which will include computerized circuits comprising craniornetric, densitometric, and other programmable functions.
The method of treatment consists of placing the tips of the lens-holders consecutively at three or snore contiguous sites of each orbital roof for periods of 2 to 4 minutes per site. This treatment is administered twice weekly for a period of up to two months. According to the pathology and the condition of the patient, treatrnent may be repeated for sirnil~~r periods as required. Patients are treated in a recumbent (or seated) position, with eyes closed. It must be emphasized that the treatment itself makes no use of the eyes ; in other words, no light is sent through retinal pathways.
The orbital roof was selected as the point of entry for photostimulation, since it consists of a thin translucent layer of bone tissue.
BEST MODE FOR CARRYING OUT THE INVENTION
In the light of practical experience with this invention, the following specifications are of particular importance - For convenience in treatment, the weight of the hand-held model of the device (batteries included) should not exceed 500gr.
- Though the lens-holders can be made of various light-weight substances, non-conductive material such as hard plastic is recommended.
- The tip of each holdex must be smooth enough to avoid scratching or causing irritation to the roofs of the orbits.
DEVICE AND TREATMENT
TECHNIC',AL FIELD AND BACKGROUND
This invention, which comprises a device and method of treatment, applies principles of photobiolo~y to the field of neuro-immune-endocrinology.
Intended for the treatment of neuro-unmune-endocrine dysfunction, the invention is designed to photostirnulate pigmented neurons in the orbital areas of the cerebral cortex with filtered light. It is known that there are direct afferent and efferent projections between the orbital areas of the cerebral cortex and the hypothalamus. The hypothalamus-pituitary-adrenal axis and the brain-bone marrow axis have a central role in neuro-immune-endocrine regula~ian. Several experiments have shown us that the method of photostimulation, with our device, of the orbital areas of the cerebral cortex can produce a modulation of the hypothalamus-pituitary-adrenal axis andlor of the brain-bone marrow axis (or conceivably of some other axis), crucial for treating the following pathologies: essential hypertension, chronic pharyngitis, rheumatoid arthritis, allergies (especi;~lly respiratory), immunodeficiency arising from any cause, cancer, systemic lupus erythematosus, eczema, psoriasis, thyroid disease, viral syndromes and other pathologies involving neuro-immune-endocrine dysfunction.
For most of the afore-mentioned diseases, conventional (pharmacological) treatment offers benefits that do not always outweigh the risks to the patient. The device we have invented uses filtered light and no medication of any kind.
Treatment with the device is painless, non-invasive and non-toxic.
Insert on page 1 before "DISCLOSURE OF THE INVENTION"
FR-A-2 746 321 discloses a deuce for 'treatment without surgery, chemotherapy or radiotherapy of (auto-immune) pathologies characterized by immunological imbalance.' The device includes means providing light and filters for blocking LTV and IR.
This device was tested on a pre-experimental basis for two months. Its effectiveness was found to be eactremely limited. Clinical improvement was not significant and not sustained for more than a week.
rt: ~: ;,t:~.~r.
DISCLOSUP;E OF THE INVENT10N
The device has optical .and electronic components with (but not restricted to) the 30 following specifications" ,ill such technical specifications concerning the device provided throughout this document are for the purpose of illustration, not of linvtation.
In the hand-held model, the optical components comprise two lens-holders made of plastic or other light-weiglht material (of cylindrical or other form). Each holder is equipped with a quartz glass (diameter : about 9mrn, thickness : 1, lmm), placed at the 35 tip, a biconvex lens (minimum SO dioptres, diameter : about 9mm, thickness : 3mm ;
or of other specifications suitable for photostimulating the orbital areas of the cerebral cortex) placed at the appropriate focal distance inside. In front of each biconvex lens is a filter with (or without) a diffuser (diameter : about 9mm, thickness : lmm), transmitting wavelengths with peaks at 350-400nm and 750-800nm (or with other peaks suitable for photostimulating the orbital areas of the cerebral cortex).
A low-s powered (2.7V-4V) medical bulb (or light source of similar power) is positioned behind each biconvex lens near the base of each holder.
In the hand-held model of the device, the two holders are mounted in a rectangular plastic casing (approx. 1:32mm x 170mm) which contains a printed circuit, battery housing (for the battery model) and a pivot mechanism for positioning the holders at different sites of the orbital roofs. ~fhe input is 6V DC (battery model), (mains model) and output is 0.5 - 3 V DC (variable) ; 50 - 300 mA . The device is equipped with an output regulator, and a digital display showing voltage or mA.
A hospital model of the device is planned which will include computerized circuits comprising craniornetric, densitometric, and other programmable functions.
The method of treatment consists of placing the tips of the lens-holders consecutively at three or snore contiguous sites of each orbital roof for periods of 2 to 4 minutes per site. This treatment is administered twice weekly for a period of up to two months. According to the pathology and the condition of the patient, treatrnent may be repeated for sirnil~~r periods as required. Patients are treated in a recumbent (or seated) position, with eyes closed. It must be emphasized that the treatment itself makes no use of the eyes ; in other words, no light is sent through retinal pathways.
The orbital roof was selected as the point of entry for photostimulation, since it consists of a thin translucent layer of bone tissue.
BEST MODE FOR CARRYING OUT THE INVENTION
In the light of practical experience with this invention, the following specifications are of particular importance - For convenience in treatment, the weight of the hand-held model of the device (batteries included) should not exceed 500gr.
- Though the lens-holders can be made of various light-weight substances, non-conductive material such as hard plastic is recommended.
- The tip of each holdex must be smooth enough to avoid scratching or causing irritation to the roofs of the orbits.
Although filters of 2nnm thickness can be used, lmm thickness is recommended to ensure efficient light transmittance.
- In order to reduce internal reflection, the surface of each filter facing the light source should have a diffuser.
- Lenses of various specifications can be used. However, lenses should meet the following requireme~its : 50 dioptres (minimum) ; 100 dioptres (maximum) ;
biconvex.
AR coating is recomnnended for the lenses and quartz glasses.
- Treatment should be: carried out in subdued lighting conditions (i.e. a low powered, shaded non-halogen lamp should be used ; fluorescent tubes must be avoided).
- Although treatment can be administered to patients in a seated position, a recumbent position is recommended since it is more conducive to relaxation.
- The duration of the treatment per orbital site should be no less than 2 minutes.
However, periods of 3-4 minutes per site tend to be particularly effective in most cases.
- Treatment twice a week yields the best results.
- Normally, treatment ;should be given for an initial period of two months.
INDUSTRIAL APPLICABILITY
Given the type of components required, this medical device can be produced at relatively low cost.
The optical and electronic parts can be produced independently and are simple to assemble. An optical compamy, for example, could subcontract the electronic part of the device (or vice versa).
With widespread use of the appliance, it would be quite easy for industry to produce more sophisticated models based on the principles and specifications outlined in the sections above. For instance, an upgraded hospital model could be used in conjunction with brain-imaging devices, EEGs and other neurological equipment.
Since the treatment entails sessions of very short duration, the cost to the patient and running costs for the therapist are limited.
It should be emphasized that all technical specifications relating to the device that are provided throughout tlhis document are for the purpose of illustration, not of limitation.
- In order to reduce internal reflection, the surface of each filter facing the light source should have a diffuser.
- Lenses of various specifications can be used. However, lenses should meet the following requireme~its : 50 dioptres (minimum) ; 100 dioptres (maximum) ;
biconvex.
AR coating is recomnnended for the lenses and quartz glasses.
- Treatment should be: carried out in subdued lighting conditions (i.e. a low powered, shaded non-halogen lamp should be used ; fluorescent tubes must be avoided).
- Although treatment can be administered to patients in a seated position, a recumbent position is recommended since it is more conducive to relaxation.
- The duration of the treatment per orbital site should be no less than 2 minutes.
However, periods of 3-4 minutes per site tend to be particularly effective in most cases.
- Treatment twice a week yields the best results.
- Normally, treatment ;should be given for an initial period of two months.
INDUSTRIAL APPLICABILITY
Given the type of components required, this medical device can be produced at relatively low cost.
The optical and electronic parts can be produced independently and are simple to assemble. An optical compamy, for example, could subcontract the electronic part of the device (or vice versa).
With widespread use of the appliance, it would be quite easy for industry to produce more sophisticated models based on the principles and specifications outlined in the sections above. For instance, an upgraded hospital model could be used in conjunction with brain-imaging devices, EEGs and other neurological equipment.
Since the treatment entails sessions of very short duration, the cost to the patient and running costs for the therapist are limited.
It should be emphasized that all technical specifications relating to the device that are provided throughout tlhis document are for the purpose of illustration, not of limitation.
Claims (12)
1. A medical device for treating neuro-immune-endocrine dysfunction by photostimulating pigmented neurons of the orbital areas of the cerebral cortex, the device including means for providing light, characterized in that the said means provides light peaking at 350-400 nm and 750-800 nm.
2. A medical device ass claimed in claim 1, wherein the means for providing light comprises a low-powered light source.
3. A medical device as claimed in claim 2, wherein the light source is a low-powered medical bulb.
4. A medical device as claimed in any one of the preceding claims, wherein the means for providing light comprises at least two lens-holders, each with a quartz glass and a lens.
5. A medical device as claimed in claim 4, wherein the means for providing light comprises a filter in front of each lens operable to transmit light peaking at 400nm and 750-800 nm.
6. A medical device as claimed in claim 5, wherein the filter is provided with a diffuser.
7. A medical device as claimed in any one of the preceding claims further comprising an output regulator for varying the voltage/current supplied to the means for providing light and a display for displaying the output voltage/current supplied.
8. A medical device as claimed in claim 7 and provided with programmable functions.
9. Use of a device as claimed in any one of claims 1 to 8 in a method of treating a medical condition by photostimulating the orbital areas of the cerebral cortex via the orbital roofs.
10. Use of a device as claimed in claim 9, wherein the medical conditions that are treatable include the following Allergies (especially respiratory), immunodeficiency, cancer, systemic lupus erythematosus, eczema, psoriasis, thyroid disease, viral syndromes, pathologies involving neuro-immune-endocrine dysfunction, essential hypertension, chronic pharyngitis, rheumatoid arthritis.
11. A method of treating a medical condition comprising photostimulating an orbital area of the cerebral cortex via an orbital roof using light peaking at 350-400 nm and 750-800 nm.
12. A method as claimed in claim 11 wherein the medical conditions that are treatable include the following:
allergies (especially respiratory), immunodeficiency, cancer, systemic lupus erythernatosus, eczema, psoriasis, thyroid disease, viral syndromes, pathologies involving neuro-immune-endocrine dysfunction, essential hypertension, chronic pharyngitis, rheumatoid arthritis.
allergies (especially respiratory), immunodeficiency, cancer, systemic lupus erythernatosus, eczema, psoriasis, thyroid disease, viral syndromes, pathologies involving neuro-immune-endocrine dysfunction, essential hypertension, chronic pharyngitis, rheumatoid arthritis.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB1998/001865 WO2000024465A1 (en) | 1998-10-23 | 1998-10-23 | Neuro-immune-endocrine regulating device and treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2348792A1 true CA2348792A1 (en) | 2000-05-04 |
Family
ID=11004782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002348792A Abandoned CA2348792A1 (en) | 1998-10-23 | 1998-10-23 | Neuro-immune-endocrine regulating device and treatment |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1123136A1 (en) |
| JP (1) | JP2002528192A (en) |
| KR (1) | KR20010107926A (en) |
| CN (1) | CN1327392A (en) |
| AU (1) | AU1049499A (en) |
| BR (1) | BR9816059A (en) |
| CA (1) | CA2348792A1 (en) |
| EA (1) | EA003414B1 (en) |
| MX (1) | MXPA01004044A (en) |
| WO (1) | WO2000024465A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2550993B1 (en) * | 2011-03-29 | 2014-12-10 | Valkee Oy | Devicefor altering dopamine Level |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4649151A (en) * | 1982-09-27 | 1987-03-10 | Health Research, Inc. | Drugs comprising porphyrins |
| US4649935A (en) * | 1984-05-21 | 1987-03-17 | Symtonic Sa | Method of treating neurovegetative disorders and apparatus therefor |
| CH676671A5 (en) * | 1989-07-03 | 1991-02-28 | Teclas Tecnologie Laser S A | |
| DE69033449T2 (en) * | 1990-01-08 | 2000-10-12 | Health Research Inc | Diving arrangement with lens and optical fiber |
| RU2071795C1 (en) * | 1994-01-31 | 1997-01-20 | Акционерное общество "Научно-производственное акционерное предприятие Алтаймедприбор" | Apparatus for producing physiotherapeutic action on patient |
| RU2074753C1 (en) * | 1994-06-09 | 1997-03-10 | Владимир Михайлович Дрюков | Device for physical therapy |
-
1998
- 1998-10-23 EA EA200100463A patent/EA003414B1/en not_active IP Right Cessation
- 1998-10-23 KR KR1020017005071A patent/KR20010107926A/en not_active Application Discontinuation
- 1998-10-23 CA CA002348792A patent/CA2348792A1/en not_active Abandoned
- 1998-10-23 BR BR9816059-1A patent/BR9816059A/en not_active IP Right Cessation
- 1998-10-23 MX MXPA01004044A patent/MXPA01004044A/en unknown
- 1998-10-23 AU AU10494/99A patent/AU1049499A/en not_active Abandoned
- 1998-10-23 CN CN98814367A patent/CN1327392A/en active Pending
- 1998-10-23 JP JP2000578066A patent/JP2002528192A/en active Pending
- 1998-10-23 WO PCT/IB1998/001865 patent/WO2000024465A1/en not_active Application Discontinuation
- 1998-10-23 EP EP98952977A patent/EP1123136A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000024465A1 (en) | 2000-05-04 |
| JP2002528192A (en) | 2002-09-03 |
| EA200100463A1 (en) | 2001-10-22 |
| EA003414B1 (en) | 2003-04-24 |
| CN1327392A (en) | 2001-12-19 |
| MXPA01004044A (en) | 2003-03-10 |
| EP1123136A1 (en) | 2001-08-16 |
| BR9816059A (en) | 2001-07-10 |
| KR20010107926A (en) | 2001-12-07 |
| AU1049499A (en) | 2000-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9138595B2 (en) | Hand-held programmable ocular light therapy apparatus and methods | |
| EP1124613B1 (en) | Photodynamic therapy apparatus | |
| US6488698B1 (en) | Portable light unit for treatment of seasonal affective disorders | |
| US5919217A (en) | Portable phototherapy unit | |
| EP0672435A1 (en) | Apparatus for treatment of rhinitis by biostimulative illumination | |
| PH30187A (en) | Pupil-tuned multifocal ophthalmic lens | |
| RU2330693C2 (en) | Colour-therapeutic light-emitting diode device | |
| GB2386560A (en) | Medical Light Therapy Apparatus. | |
| CN1008600B (en) | Solar ray energy radiating device for use in medical treatment | |
| CA2348792A1 (en) | Neuro-immune-endocrine regulating device and treatment | |
| CN1065003A (en) | The medicine cap of treatment eye and ear diseases | |
| CN206120877U (en) | Add hot type burden ions introduced into atomizing device | |
| US4766899A (en) | Solar ray energy radiation device for use in medical treatment | |
| WO1997000653A1 (en) | Method of improving visual function and associated device | |
| US20140330350A1 (en) | Device for stimulation of the brain by laser circularly or elliptically polarized light | |
| Gallert | New light on therapeutic energies | |
| RU128494U1 (en) | DEVICE FOR IMPACT ON HUMAN BIORITHMS | |
| CN1135364A (en) | Optical-spectrum therapeutic instrument | |
| CN87202100U (en) | Color and light eyesight-increased instrument for afterimage | |
| CN1275412A (en) | Phototherapy unit | |
| CN100386124C (en) | Microcomputer multi-frequency photo therapeutic instrument | |
| RU25415U1 (en) | DEVICE FOR TREATMENT OF ALCOHOLISM | |
| CN2046021U (en) | Double red light-gathering therapeutic instrument for weak sight | |
| Duus | Weiss, Joseph (1993). How Psychotherapy Works: Process and Technique. New York, Guilford Press, pp. 224, $27.95 | |
| CN1076872A (en) | Prevention and treatment glasses for migraine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |